Effect of Antihypertensive Drugs on Glaucoma Patients

NCT ID: NCT04943107

Last Updated: 2021-06-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It has been reported that among Asian non-glaucomatous, antihypertensive medications were associated with retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness. In order to explore whether antihypertensive medications would influence the neuropathy among glaucomatous population, we designed a cross-sectional observational study to analyze the retinal status among glaucoma patients with use of antihypertensive medication.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

we designed a cross-sectional obeservational study to analyze the retinal status among glaucoma patients with use of hyertensive medication.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

healthy control

adults without glaucoma history or hypertension history

no intervention

Intervention Type OTHER

no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..

glaucoma patients

adults with primary glaucoma history; without glaucoma-related operation history; without hypertension history

no intervention

Intervention Type OTHER

no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..

hypertension patients

adults with primary hypertension history; without glaucoma history

no intervention

Intervention Type OTHER

no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..

glaucoma+hypertension

adults with primary glaucoma history and primary hypertension history; without glaucoma-related operation history

no intervention

Intervention Type OTHER

no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

no intervention

no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age no less than 18 years

* best corrected visual acuity better than decimal 0.3

Exclusion Criteria

* secondary glaucoma

* secondary hypertension
* glaucoma-related operation history
* pregnancy or lactation period
* uncooperative with retinal examination
* severe opacity with refracting media in eye
* severe retinal diseases and neuropathy
* congenital retinal optic nerve abnormality
* other systemic diseases that influence hypertension and glaucoma assessment
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kaijun Wang, MD

Role: PRINCIPAL_INVESTIGATOR

Second Affiliated Hospital of College of Medicine, Zhejiang University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

2nd Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kaijun Wang, MD

Role: CONTACT

+86 13600529217

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kaijun Wand, MD

Role: primary

+86 1360052917

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-0287

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Nicotinamide and Glaucoma
NCT05916066 COMPLETED NA